Role of immunohistochemistry for interobserver agreement of Peritoneal Regression Grading Score (PRGS) in peritoneal metastasis.

[1]  I. D. de Hingh,et al.  The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases: a narrative review. , 2021, Journal of gastrointestinal oncology.

[2]  C. Yardin,et al.  10 ns PEFs induce a histological response linked to cell death and cytotoxic T-lymphocytes in an immunocompetent mouse model of peritoneal metastasis , 2021, Clinical and Translational Oncology.

[3]  O. Sgarbura,et al.  Pressurized Intraperitoneal Aerosol Chemotherapy Enhanced by Electrostatic Precipitation (ePIPAC) for Patients with Peritoneal Metastases , 2020, Annals of Surgical Oncology.

[4]  A. Strippoli,et al.  Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis. , 2020, Surgical oncology.

[5]  O. Sgarbura,et al.  Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification? , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  S. Detlefsen,et al.  Pleura and Peritoneum , 2020 .

[7]  S. Detlefsen,et al.  Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC , 2020, Journal of Clinical Pathology.

[8]  J. Fontaine,et al.  Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis , 2020, Histopathology.

[9]  L. Lundell,et al.  Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study , 2020, Clinical & Experimental Metastasis.

[10]  Mahesh D. Patel,et al.  Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  C. Sempoux,et al.  Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis , 2019, Histopathology.

[12]  S. Detlefsen,et al.  Detection of free intraperitoneal tumour cells in peritoneal lavage fluid from patients with peritoneal metastasis before and after treatment with pressurised intraperitoneal aerosol chemotherapy (PIPAC) , 2019, Journal of Clinical Pathology.

[13]  M. Pocard,et al.  Evaluation of a new histological grading system for assessing the response to chemotherapy of peritoneal metastases from colorectal cancer: A mouse model study. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  S. Detlefsen,et al.  Pressurized IntraPeritoneal Aerosol Chemotherapy with one minute of electrostatic precipitation (ePIPAC) is feasible, but the histological tumor response in peritoneal metastasis is insufficient. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  L. Lundell,et al.  Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure , 2018, Pleura and peritoneum.

[16]  W. Solass,et al.  Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study , 2018, Gastroenterology research and practice.

[17]  S. Detlefsen,et al.  Treatment of peritoneal carcinomatosis with Pressurized IntraPeritoneal Aerosol Chemotherapy – PIPAC-OPC2 , 2018, Pleura and peritoneum.

[18]  S. Detlefsen,et al.  University of Southern Denmark Prospective , single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy ( PIPAC ) for peritoneal metastasis , 2018 .

[19]  S. Somashekhar,et al.  First Indian Study on Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Procedure for Advanced Peritoneal Carcinomatosis Secondary to Epithelial Ovarian Cancer , 2018, Indian Journal of Gynecologic Oncology.

[20]  J. Sehouli,et al.  The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German “Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)”, the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology , 2018, Archives of Gynecology and Obstetrics.

[21]  T. Khosrawipour,et al.  Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma , 2017, PloS one.

[22]  S. Detlefsen,et al.  Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) , 2017, Clinical & Experimental Metastasis.

[23]  N. Demartines,et al.  Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis , 2017, The British journal of surgery.

[24]  C. Sempoux,et al.  Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS) , 2016, Pleura and peritoneum.

[25]  W. Solass,et al.  Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis , 2016, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[26]  L. Sobin,et al.  A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process , 2016, The American journal of surgical pathology.

[27]  W. Solass,et al.  Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  Urs Giger-Pabst,et al.  Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.

[29]  Seung‐Mo Hong,et al.  Prevalence and Clinical Significance of Acellular Mucin in Locally Advanced Rectal Cancer Patients Showing Pathologic Complete Response to Preoperative Chemoradiotherapy , 2013, The American journal of surgical pathology.

[30]  W. Solass,et al.  Renal and Hepatic Toxicities After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) , 2013, Annals of Surgical Oncology.

[31]  D. Driman,et al.  Infarct-like Necrosis: A Distinct Form of Necrosis Seen in Colorectal Carcinoma Liver Metastases Treated With Perioperative Chemotherapy , 2012, The American journal of surgical pathology.

[32]  W. Solass,et al.  Description of a novel approach for intraperitoneal drug delivery and the related device , 2011, Surgical Endoscopy.

[33]  M. Dutreix,et al.  Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept , 2011, Surgical Endoscopy.